These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 10475181)

  • 1. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.
    Lancet; 1999 Aug; 354(9180):708-15. PubMed ID: 10475181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators.
    Lancet; 1999 Aug; 354(9180):701-7. PubMed ID: 10475180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
    Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
    Wallentin L
    Haemostasis; 2000; 30 Suppl 2():108-13; discussion 106-7. PubMed ID: 11251353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
    Wallentin L; Lagerqvist B; Husted S; Kontny F; Ståhle E; Swahn E
    Lancet; 2000 Jul; 356(9223):9-16. PubMed ID: 10892758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) Trials.
    Damman P; van Geloven N; Wallentin L; Lagerqvist B; Fox KA; Clayton T; Pocock SJ; Hirsch A; Windhausen F; Tijssen JG; de Winter RJ
    JACC Cardiovasc Interv; 2012 Feb; 5(2):191-9. PubMed ID: 22361604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
    Lagerqvist B; Husted S; Kontny F; Ståhle E; Swahn E; Wallentin L;
    Lancet; 2006 Sep; 368(9540):998-1004. PubMed ID: 16980115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease.
    Lagerqvist B; Diderholm E; Lindahl B; Husted S; Kontny F; Ståhle E; Swahn E; Venge P; Siegbahn A; Wallentin L
    Heart; 2005 Aug; 91(8):1047-52. PubMed ID: 16020594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome.
    Damman P; Hirsch A; Windhausen F; Tijssen JG; de Winter RJ;
    J Am Coll Cardiol; 2010 Mar; 55(9):858-64. PubMed ID: 20045278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial.
    Tegn N; Abdelnoor M; Aaberge L; Endresen K; Smith P; Aakhus S; Gjertsen E; Dahl-Hofseth O; Ranhoff AH; Gullestad L; Bendz B;
    Lancet; 2016 Mar; 387(10023):1057-1065. PubMed ID: 26794722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).
    Wallentin L; Husted S; Kontny F; Swahn E
    Am J Cardiol; 1997 Sep; 80(5A):61E-63E. PubMed ID: 9296473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.
    Wallentin L; Lindhagen L; Ärnström E; Husted S; Janzon M; Johnsen SP; Kontny F; Kempf T; Levin LÅ; Lindahl B; Stridsberg M; Ståhle E; Venge P; Wollert KC; Swahn E; Lagerqvist B;
    Lancet; 2016 Oct; 388(10054):1903-1911. PubMed ID: 27585757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial.
    Fox KA; Poole-Wilson P; Clayton TC; Henderson RA; Shaw TR; Wheatley DJ; Knight R; Pocock SJ
    Lancet; 2005 Sep 10-16; 366(9489):914-20. PubMed ID: 16154018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease.
    Janzon M; Levin LA; Swahn E
    Eur Heart J; 2002 Jan; 23(1):31-40. PubMed ID: 11741360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy.
    Lindmark E; Diderholm E; Wallentin L; Siegbahn A
    JAMA; 2001 Nov; 286(17):2107-13. PubMed ID: 11694151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization.
    Husted SE; Wallentin L; Lagerqvist B; Kontny F; Ståhle E; Swahn E
    Eur Heart J; 2002 Aug; 23(15):1213-8. PubMed ID: 12127923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
    Swahn E; Wallentin L
    Am J Cardiol; 1997 Sep; 80(5A):25E-29E. PubMed ID: 9296466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy.
    Lindahl B; Lindbäck J; Jernberg T; Johnston N; Stridsberg M; Venge P; Wallentin L
    J Am Coll Cardiol; 2005 Feb; 45(4):533-41. PubMed ID: 15708700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study.
    Lagerqvist B; Husted S; Kontny F; Näslund U; Ståhle E; Swahn E; Wallentin L;
    J Am Coll Cardiol; 2002 Dec; 40(11):1902-14. PubMed ID: 12475448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction.
    Kakkar VV; Iyengar SS; De Lorenzo F; Hargreaves JR; Kadziola ZA;
    Indian Heart J; 2000; 52(5):533-9. PubMed ID: 11256775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.